Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 and first-half 2026 financial results announced for periods ended June 30, 2026.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the disclosed financial results and management commentary
- Investor focus: revenue, cash position, operating expenses, and pipeline updates in the attached release
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss widened to $36.7M, or $2.34 per share, from $28.7M, reflecting continued clinical-stage cash burn
- Cash rose to $219.5M by August 6 after $100.0M Oxford funding, extending resources for trials and potential commercialization
- Oxford amendment provides $225.0M additional borrowing capacity, subject to company request and Oxford discretion
- Ozekibart BLA accepted, with FDA PDUFA goal date April 14, 2027, creating a defined regulatory catalyst in conventional chondrosarcoma
- Upcoming catalysts include INBRX-106 PFS data in Q3 2026 and ozekibart colorectal cancer interim results in Q1 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.